At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 260 enrolled
Drug / intervention
Cerdulatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)
In Brief
A Phase 2 clinical trial evaluating Cerdulatinib and Rituximab for Follicular Lymphoma (FL/Indolent NHL) and 4 related conditions. Completed, enrolled 260 participants across 23 sites.
Detailed Summary
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
CountriesUnited States
CollaboratorsPortola Pharmaceuticals
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedNov 2013
Primary CompletionDec 2020
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartAug 30, 2013
Primary CompletionDec 15, 2020
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 12.6 years ago
Interventions
Cerdulatinibdrug
Oral capsule
Rituximabbiological
IV infusion